Saudi Press

Saudi Arabia and the world
Saturday, Aug 02, 2025

COVID-19: Delaying second dose of Pfizer jab may leave elderly at risk of catching South African variant, study suggests

COVID-19: Delaying second dose of Pfizer jab may leave elderly at risk of catching South African variant, study suggests

Lab tests showed that one dose of the vaccine may not stimulate the immune system to produce enough antibodies to kill the virus.

Delaying the second dose of the Pfizer jab – the current government strategy - may leave some elderly patients at risk of infection by the South African variant, new research suggests.

Lab tests by scientists at Cambridge University showed that one dose of the vaccine may not stimulate the immune system to produce enough antibodies to kill the virus.

Only after a second dose would antibody levels be protective, according to preliminary data in the study, which has not yet been peer-reviewed.

Meanwhile, the South African variant has a mutation called E484K that helps it evade the immune system.

SOUTH AFRICAN VARIANT CASES



Some samples of the Kent variant have now been detected with the same mutation.

The Cambridge researchers tested blood samples from 26 people, 15 of them over 80, who had received one dose of the Pfizer jab against synthetic versions of both variants.

Antibodies in all volunteers were sufficient to kill the Kent variant.

But when the E484K mutation was added 10 times more antibodies were needed to neutralise the virus.

According to researchers, seven people had antibody levels that were insufficient to kill the virus after one dose of the vaccine, all of them over 80.

Only after a second dose, given three weeks later, were their antibody levels boosted to a level that killed the virus.

The study comes on the day Sky News analysis showed the number of deaths in the second wave of COVID-19 infections has now overtaken the number from the first.

Dr Dami Collier, one of the co-investigators, said: "Our data suggest that a significant proportion of people aged over 80 may not have developed protective neutralising antibodies against infection three weeks after their first dose of the vaccine.

"But it's reassuring to see that after two doses, serum from every individual was able to neutralise the virus."

Professor Ravi Gupta, the lead researcher, said: "Our work suggests the vaccine is likely to be less effective when dealing with this (E484K) mutation.

"B1.1.7 [the Kent variant] will continue to acquire mutations seen in the other variants of concern, so we need to plan for the next generation of vaccines to have modifications to account for new variants.

"We also need to scale up vaccines as fast and as broadly as possible to get transmission down globally."

A Department for Health and Social Care (DHSC) spokesperson said the decision to change vaccine dosage intervals (to spread them further apart) had come after a "thorough review of data" which showed the Pfizer/BioNTech vaccine was 89% effective in protection against COVID between 15 to 21 days after the first dose.

A DHSC statement said today's study had "assessed just one aspect of immunity, on a small cohort" and that getting vaccines deployed as quickly as possible to those at risk remained "our number one priority".

It concluded: "The Government is closely following the guidance of the Joint Committee on Vaccination and Immunisation and the UK's four Chief Medical Officers, which recommends we prioritise first doses of vaccine for as many people as possible"

The E484K variant helps the coronavirus evade the immune system and was found in 11 samples of some 200,000 that have been sequenced.

Sky's science correspondent Thomas Moore said the discovery of the E484K mutation was a "worrying development," as it could reduce the effectiveness of COVID vaccines and could also mean those who had been previously infected could be re-infected.

He said the evolution of E484K meant the virus had effectively "developed a superpower" which enabled it to not only infect cells, but also to beat the immune system.

"It changes shape so antibodies don't recognise it in the same way, and the fact that this mutation has been now picked up in some samples of the Kent variant is a twist - a worrying development," said Thomas Moore.

Newsletter

Related Articles

Saudi Press
0:00
0:00
Close
British Tourist Dies Following Hair Transplant in Turkey, Police Investigate
WhatsApp Users Targeted in New Scam Involving Account Takeovers
Trump Deploys Nuclear Submarines After Threats from Former Russian President Medvedev
Germany’s Economic Breakdown and the Return of Militarization: From Industrial Collapse to a New Offensive Strategy
IMF Upgrades Global Growth Forecast as Weaker Dollar Supports Outlook
Politics is a good business: Barack Obama’s Reported Net Worth Growth, 1990–2025
"Crazy Thing": OpenAI's Sam Altman Warns Of AI Voice Fraud Crisis In Banking
Japanese Prime Minister Vows to Stay After Coalition Loses Upper House Majority
President Trump Diagnosed with Chronic Venous Insufficiency After Leg Swelling
Man Dies After Being Pulled Into MRI Machine Due to Metal Chain in New York Clinic
FIFA Pressured to Rethink World Cup Calendar Due to Climate Change
"Can You Hit Moscow?" Trump Asked Zelensky To Make Putin "Feel The Pain"
Nvidia Becomes World’s First Four‑Trillion‑Dollar Company Amid AI Boom
Iranian President Reportedly Injured During Israeli Strike on Secret Facility
Kurdistan Workers Party Takes Symbolic Step Towards Peace in Northern Iraq
BRICS Expands Membership with Indonesia and Ten New Partner Countries
Elon Musk Founds a Party Following a Poll on X: "You Wanted It – You Got It!"
AI Raises Alarms Over Long-Term Job Security
Saudi Arabia Maintains Ties with Iran Despite Israel Conflict
Russia Formally Recognizes Taliban Government in Afghanistan
Mediators Edge Closer to Israel-Hamas Ceasefire Agreement
Emirates Airline Expands Market Share with New $20 Million Campaign
House Oversight Committee Subpoenas Former Jill Biden Aide Amid Investigation into Alleged Concealment of President Biden's Cognitive Health
Amazon Reaches Major Automation Milestone with Over One Million Robots
Meta Announces Formation of Ambitious AI Unit, Meta Superintelligence Labs
China Unveils Miniature Insect-Like Surveillance Drone
Marc Marquez Claims Victory at Dutch Grand Prix Amidst Family Misfortune
Iran Executes Alleged Israeli Spies and Arrests Hundreds Amid Post-War Crackdown
Trump Asserts Readiness for Further Strikes on Iran Amid Nuclear Tensions
Iran's Parliament Votes to Suspend Cooperation with Nuclear Watchdog
Trump Announces Upcoming US-Iran Meeting Amid Controversial Airstrikes
Trump Moves to Reshape Middle East Following Israel-Iran Conflict
NATO Leaders Endorse Plan for Increased Defence Spending
U.S. Crude Oil Prices Drop Below $65 Amid Market Volatility
Explosions Rock Doha as Iranian Missiles Target Qatar
“You Have 12 Hours to Flee”: Israeli Threat Campaign Targets Surviving Iranian Officials
Oman Set to Introduce Personal Income Tax, First in Gulf
Germany and Italy Under Pressure to Repatriate $245bn of Gold from US Vaults
Iran Intensifies Crackdown on Alleged Mossad Operatives After Sabotage Claims
Trump Praises Iran’s ‘Very Weak’ Response After U.S. Strikes and Presses Israel to Pursue Peace
WATCH: Israeli forces show the aftermath of a massive airstrike at Iran's Isfahan nuclear site
We have new information and breaking details to share about what is shaping up to be a historic air campaign tonight
Six Massive Bombs Dropped on Fordow; Trump: 'A Historic Moment for the U.S., Israel, and the World'
Fordow: Deeply Buried Iranian Enrichment Site in U.S.–Israel Crosshairs
United States Conducts Precision Strikes on Iran’s Nuclear Sites
US strikes Iran nuclear sites, Trump says
Pakistan to nominate Trump for Nobel Peace Prize.
Israel Confirms Assassination of Quds Force Commander in Tehran
16 Billion Login Credentials Leaked in Unprecedented Cybersecurity Breach
Senate hearing on who was 'really running' Biden White House kicks off
×